文献速递流行病学与生物统计真实世界研究与卫生经济

实用性试验中并行经济学评价的样本量报告质量差且样本量不足:一项横断面调查

Poor sample size reporting quality and insufficient sample size in economic evaluations conducted alongside pragmatic trials: a cross-sectional survey.
PubMed 文献 · J Clin Epidemiol · 2024-09-21

该横断面调查基于PubMed和OVID数据库2010年1月1日至2022年4月24日的实用性随机对照试验(pRCT)数据,评估pRCT中并行经济学评价的样本量报告质量并估算其检验效能。152项符合标准的研究中仅9项(5.9%)在估算样本量时考虑经济学结局,仅1项据此调整样本量;26项可进行效能分析的研究中,14项(53.8%)QALYs经济学评价效能低于临床主要终点。作者建议未来pRCT应在方案中报告如何基于经济学结局确定或调整样本量。

要点

  • 152项pRCT中仅9项(5.9%)估算样本量时考虑经济学结局,仅1项据此调整样本量。
  • 26项可效能分析研究中,14项(53.8%)QALYs经济学评价效能低于临床主要终点。
  • 作者建议未来pRCT方案应报告基于经济学结局确定或调整样本量的方法。

核心结论

  • pRCT并行经济学评价中对经济学结局的样本量计算考虑有限且报告不足,可能影响结果的可靠性和外推性。
  • 作者建议未来开展经济学评价的实用性试验应在方案中报告如何基于经济学结局确定或调整样本量,以提高透明度和证据质量。

研究设计与样本

  • 横断面调查,数据来源为PubMed和OVID数据库2010年1月1日至2022年4月24日可获取的pRCT数据。
  • 电子检索识别715项研究,152项符合纳入标准,其中26项有足够数据进行效能分析。
  • 由两组独立审稿人筛选文章,三组审稿人分别提取数据;采用描述性统计呈现纳入研究的一般特征,并对有足够数据的临床和经济结局进行统计效能分析。

主要发现

  • 152项试验中仅9项(5.9%)在估算样本量时考虑经济学结局,仅1项据此调整样本量。
  • 基于试验的经济学评价和临床试验的效能值范围分别为2.56%至100%和3.21%至100%。
  • 无论何种视角,26项研究中有14项(53.8%)QALYs经济学评价的效能值低于临床主要终点。
  • 从医疗保健视角和社会视角,分别有11/24项(45.8%)和8/13项(61.5%)研究QALYs经济学评价效能低于临床主要终点。
  • 从医疗保健视角和社会视角,非QALYs经济学评价效能值在4项研究中有3项(75%)可能高于临床试验。

临床怎么用

  • 作者建议未来开展经济学评价的实用性试验应在方案中报告如何基于经济学结局确定或调整样本量,以提高透明度和证据质量。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Economic evaluations based on well-designed and -conducted pragmatic randomized controlled trials (pRCTs) can provide valuable evidence on the cost-effectiveness of interventions, enhancing the relevance and applicability of findings to healthcare decision-making. However, economic evaluation outcomes are seldom taken into consideration during the process of sample size calculation in pragmatic trials. The reporting quality of sample size and information on its calculation in economic evaluations that are well-suited to pRCTs remain unknown. This study aims to assess the reporting quality of sample size and estimate the power values of economic evaluations in pRCTs. STUDY DESIGN AND SETTING: We conducted a cross-sectional survey using data of pRCTs available from PubMed and OVID from 1 January 2010 to 24 April 2022. Two groups of independent reviewers identified articles; three groups of reviewers each extracted the data. Descriptive statistics presented the general characteristics of included studies. Statistical power analyses were performed on clinical and economic outcomes with sufficient data. RESULTS: The electronic search identified 715 studies and 152 met the inclusion criteria. Of these, 26 were available for power analysis. Only 9 out of 152 trials (5.9%) considered economic outcomes when estimating sample size, and only one adjusted the sample size accordingly. Power values for trial-based economic evaluations and clinical trials ranged from 2.56% to 100% and 3.21%-100%, respectively. Regardless of the perspectives, in 14 out of the 26 studies (53.8%), the power values of economic evaluations for quality-adjusted life years (QALYs) were lower than those of clinical trials for primary endpoints (PEs). In 11 out of the 24 (45.8%) and in 8 out of the 13 (61.5%) studies, power values of economic evaluations for QALYs were lower than those of clinical trials for PEs from the healthcare and societal perspectives, respectively. Power values of economic evaluations for non-QALYs from the healthcare and societal perspectives were potentially higher than those of clinical trials in 3 out of the 4 studies (75%). The power values for economic outcomes in Q1 were not higher than those for other journal impact factor quartile categories. CONCLUSION: Theoretically, pragmatic trials with concurrent economic evaluations can provide real-world evidence for healthcare decision makers. However, in pRCT-based economic evaluations, limited consideration, and inadequate reporting of sample-size calculations for economic outcomes could negatively affect the results' reliability and generalisability. We thus recommend that future pragmatic trials with economic evaluations should report how sample sizes are determined or adjusted based on the economic outcomes in their protocols to enhance their transparency and evidence quality.

来源:J Clin Epidemiol,查看原文。版权归原作者所有。

引用

  1. Wu C, Hao J, Xin Y, et al. Poor sample size reporting quality and insufficient sample size in economic evaluations conducted alongside pragmatic trials: a cross-sectional survey. J Clin Epidemiol. 2024. PMID: 39307404. doi:10.1016/j.jclinepi.2024.111535

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。